Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinc acexamate is a zinc salt of acexamic acid (6-acetamidohexanoic acid) that functions primarily as a cytoprotective and anti-ulcer agent. It was developed by Laboratorios Viñas and has been used clinically for the treatment of gastric and duodenal ulcers. Its mechanism involves the stimulation of gastric mucus production, inhibition of histamine release from mast cells, and the promotion of tissue repair through the delivery of zinc ions. Beyond its gastroprotective applications, zinc acexamate is being investigated for its potential therapeutic benefits in advanced chronic liver disease, where it may help address zinc deficiency, reduce ammonia levels, and mitigate hepatic encephalopathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc acexamate.